Related Experiment Videos
Release of LPL activity after intravenous injection of a low molecular weight heparin
British Journal of Clinical Pharmacology
|December 1, 1983
Abstract:
A low molecular weight heparin (MW 4000-6000), PK 10169 (Pharmuka), with much reduced anticoagulant in vitro capacity, retains the properties of the standard heparin in releasing lipoprotein lipase and hepatic lipase activity after being injected intravenously.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2021
Investigation of primary immune deficiency after severe bacterial infection in children: A population-based study in western France.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2021
Expert judgment based multicriteria decision models to assess the risk of pesticides on reproduction failures of grey partridge.
SAR and QSAR in environmental research·2017
Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines.
Pediatric hematology and oncology·2016
Prediction of the endocrine disruption profile of pesticides.
SAR and QSAR in environmental research·2015
Lithium-related adverse drug reactions in children: A case-control study comparing lithium to second-generation antipsychotics in VigiBase.
British journal of clinical pharmacology·2026
Prevalence of pregnancy and birth outcomes following biologic exposure in immune-mediated inflammatory diseases: A population-based study.
British journal of clinical pharmacology·2026
Safety and pharmacokinetics of inhaled aloxistatin: A first-in-human phase 1 dose escalation trial.
British journal of clinical pharmacology·2026
Physiologically based pharmacokinetic modelling and dose optimization of tedizolid in paediatric patients.
British journal of clinical pharmacology·2026
Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.
British journal of clinical pharmacology·2026
Safety, pharmacodynamics and pharmacokinetics of a novel JAK1-selective inhibitor, IN-115314, in healthy participants: A first-in-human study.
British journal of clinical pharmacology·2026
Reninoma in an adolescent boy with negative selective renal vein sampling: a case report and review of the literature.
Frontiers in endocrinology·2026
The Red Flags Were Missing, the Indication Was Not: Genetic Testing in Heart Failure and Cardiomyopathy.
Methodist DeBakey cardiovascular journal·2026
HLX11: A Pertuzumab Biosimilar.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026